National Bank of Canada
FATE icon

National Bank of Canada’s Fate Therapeutics FATE Stock Holding History

National Bank of Canada’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-410
Closed -$1.34K – 2851
2024
Q2 		$1.34K Buy
410
+10
+3% +$44 ﹤0.01% 2471
2024
Q1 		$1.63K Sell
400
-6,600
-94% -$40.9K ﹤0.01% 2480
2023
Q4 		$25.8K Sell
7,000
-5,000
-42% -$11.8K ﹤0.01% 1947
2023
Q3 		$22.9K Buy
+12,000
New +$39.8K ﹤0.01% 2001
2023
Q1 		– Sell
-500
Closed -$5.04K – 2753
2022
Q4 		$5.04K Hold
500
– – ﹤0.01% 2335
2022
Q3 		$11K Sell
500
-500
-50% -$14.4K ﹤0.01% 2153
2022
Q2 		$25K Buy
+1,000
New +$27.6K ﹤0.01% 2001

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

National Bank of Canada's FATE Position: Q3 2024 in Review

National Bank of Canada sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 410 shares — an estimated $1.34K sold.

National Bank of Canada first reported a position in FATE in Q2 2022 and held it in 7 quarters. The position peaked at $25.8K in Q4 2023. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • National Bank of Canada reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • National Bank of Canada sold 410 Fate Therapeutics shares in Q3 2024, an estimated $1.34K.
  • National Bank of Canada first reported a position in Fate Therapeutics in Q2 2022 and held it in 7 quarters.
  • National Bank of Canada's Fate Therapeutics position peaked at $25.8K in Q4 2023.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.